Aesther, a special purpose acquisition company (“SPAC”) and Ocean Biomedical Inc. (NASDAQ: OCEA), a next-generation biopharma company, recently announced stockholder approval of all proposals related to the previously disclosed proposed business combination between Aesther and Ocean. According to the update, the approvals were secured at a special meeting of stockholders held on Feb. 3, 2023. The combined company, Ocean Biomedical, and its Class A common stock commenced trading on the Nasdaq Capital Market under the symbol OCEA. “I’m pleased that the majority of shareholders have, through their votes in favor of going public, reaffirmed their belief in our vision for the company,” said Dr. Chirinjeev Kathuria, Ocean Biomedical co-founder and executive chairman of the board of directors. “The business combination with Aesther brings us one step closer to realizing our foremost goals as an innovative life sciences company.”
To view the full press release, visit https://ibn.fm/9hE5M
About Ocean Biomedical Inc.
Ocean Biomedical is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most. To learn more, visit www.oceanbiomedical.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.